Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 178

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group

Open access
Hillengass, J, Moulopoulos, L A, Delorme, S, Koutoulidis, V, Mosebach, J, Hielscher, T, Drake, M, Rajkumar, S V, Oestergaard, B, Abildgaard, N, Hinge, M, Plesner, T, Suehara, Y, Matsue, K, Withofs, N, Caers, J, Waage, A, Goldschmidt, H, Dimopoulos, M A, Lentzsch, S, Durie, B, Terpos, E · 2017 · Blood Cancer Journal

Abstract

For decades, conventional skeletal survey (CSS) has been the standard imaging technique for multiple myeloma (MM). However, recently whole-body computed tomography (WBCT) has been implemented into the diagnostic criteria of MM. This analysis compares sensitivity and prognostic significance of WBCT and CSS in patients with smoldering MM (SMM) and MM. Fifty-four of 212 patients (25.5%) had a negative CSS and a positive WBCT for osteolytic lesions (P<0.0001). Of 66 patients with SMM based on CSS, 12 (22.2%) had osteolytic lesions on WBCT. In comparison, WBCT failed to detect some bone destructions in the appendicular skeleton possibly due to limitations of the field of view. Presence of lytic bone lesions in WBCT was of borderline prognostic significance (P=0.051) for SMM patients, with a median time to progression of 38 versus 82 months for those without bone destructions. In conclusion, WBCT identifies significantly more sites of bone destruction than CSS. More than 20% of patients with SMM according to CSS have in fact active MM detectable with WBCT. On the basis of this and other studies, WBCT (either computed tomography (CT) alone or as part of a positron emission tomography-CT protocol) should be considered the current standard for the detection of osteolytic lesions in MM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bcj.2017.78

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 25

  1. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O et al. International Myeloma Working Group Consensus Statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009; 23: 1545–1556. · DOI · Paper page
  2. D’Sa S, Abildgaard N, Tighe J, Shaw P, Hall-Craggs M . Guidelines for the use of imaging in the management of myeloma. Br J Haematol 2007; 137: 49–63. · DOI
  3. Durie BG, Salmon SE . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–854. · DOI · Paper page
  4. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749–757. · DOI · Paper page
  5. Edelstyn GA, Gillespie PJ, Grebbell FS . The radiological demonstration of osseous metastases. Experimental observations. Clin Radiol 1967; 18: 158–162. · doi:10.1016/s0009-9260(67)80010-2
  6. Wolf MB, Murray F, Kilk K, Hillengass J, Delorme S, Heiss C et al. Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease. Eur J Radiol 2014; 83: 1222–1230. · doi:10.1016/j.ejrad.2014.02.008
  7. Mahnken AH, Wildberger JE, Gehbauer G, Schmitz-Rode T, Blaum M, Fabry U et al. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR Am J Roentgenol 2002; 178: 1429–1436. · doi:10.2214/ajr.178.6.1781429
  8. Kröpil P, Fenk R, Fritz LB, Blondin D, Kobbe G, Mödder U et al. Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma. Eur Radiol 2008; 18: 51–58. · doi:10.1007/s00330-007-0738-3
  9. Hinge M, Andersen KT, Lund T, Jørgensen HB, Holdgaard PC, Ormstrup TE et al. Baseline bone involvement in multiple myeloma - a prospective comparison of conventional X-ray, low-dose computed tomography, and 18flourodeoxyglucose positron emission tomography in previously untreated patients. Haematologica 2016; 101: e415–e418. · DOI
  10. Princewill K, Kyere S, Awan O, Mulligan M . Multiple myeloma lesion detection with whole body CT versus radiographic skeletal survey. Cancer Invest 2013; 31: 206–211. · doi:10.3109/07357907.2013.764565
  11. Schreiman JS, McLeod RA, Kyle RA, Beabout JW . Multiple myeloma: evaluation by CT. Radiology 1985; 154: 483–486. · doi:10.1148/radiology.154.2.3966137
  12. Horger M, Claussen CD, Bross-Bach U, Vonthein R, Trabold T, Heuschmid M et al. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography. Eur J Radiol 2005; 54: 289–297. · doi:10.1016/j.ejrad.2004.04.015
  13. Siontis B, Kumar S, Dispenzieri A, Drake MT, Lacy MQ, Buadi F et al. Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer J 2015; 5: e364. · DOI
  14. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O et al. A prospective comparison of 18 F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007; 92: 50–55. · DOI · Paper page
  15. Fonti R, Salvatore B, Quarantelli M, Sirignano C, Segreto S, Petruzziello F et al. 18 F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med 2008; 49: 195–200. · DOI · Paper page
  16. Baur-Melnyk A, Buhmann S, Becker C, Schoenberg SO, Lang N, Bartl R et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol 2008; 190: 1097–1104. · DOI
  17. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A et al. Prognostic relevance of 18- F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 2011; 118: 5989–5995. · DOI · Paper page
  18. Bartel TB, Haessler J, Brown TLY, Shaughnessy JD, van Rhee F, Anaissie E et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009; 114: 2068–2076. · DOI · Paper page
  19. Hillengass J, Ayyaz S, Kilk K, Weber M-A, Hielscher T, Shah R et al. Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica 2012; 97: 1757–1760. · DOI
  20. Surov A, Bach AG, Tcherkes A, Schramm D . Non-osseous incidental findings in low-dose whole-body CT in patients with multiple myeloma. Br J Radiol 2014; 87: 20140185. · DOI
  21. Nishida Y, Matsue Y, Suehara Y, Fukumoto K, Fujisawa M, Takeuchi M et al. Clinical and prognostic significance of bone marrow abnormalities in the appendicular skeleton detected by low-dose whole-body multidetector computed tomography in patients with multiple myeloma. Blood Cancer J 2015; 5: e329. · DOI
  22. Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E et al. European Myeloma Network Guidelines for the management of multiple myeloma-related complications. Haematologica 2015; 100: 1254–1266. · DOI · Paper page
  23. Terpos E, Dimopoulos MA, Moulopoulos LA . The role of imaging in the treatment of patients with multiple myeloma in 2016. Am Soc Clin Oncol Educ Book 2016; 35: e407–e417. · DOI
  24. Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol 2015; 33: 657–664. · DOI · Paper page
  25. Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 2017; 18: e206–e217. · DOI · Paper page

Cited by

See all 178

Metadata

Authors
Hillengass, J., Moulopoulos, L. A., Delorme, S., Koutoulidis, V, Mosebach, J., Hielscher, T., Drake, M., Rajkumar, S. V., Oestergaard, B., Abildgaard, N., Hinge, M., Plesner, T., Suehara, Y., Matsue, K., Withofs, N., Caers, J., Waage, A., Goldschmidt, H., Dimopoulos, M. A., Lentzsch, S., Durie, B., & Terpos, E.
Venue
Blood Cancer Journal
Published
2017-08-25
Volume
7
Issue
8
Pages
e599-e599
ISSN
2044-5385 (ISSN-L)
OpenAlex
W2746958153
Cited by
178
References
1
FWCI
11.04
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.